The effect of dyslipidemic drugs on mortality: A meta-analysis

Indian Journal of Pharmacology

Volumn 41, Issue 1, 2009, Pages 4-8

  Jain, Shuchi ^a   Vaishnavi, Vikas ^a   Chakraborty, Bhaswat S ^a  

^a Cadila Pharmaceuticals Limited   (India)

Author keywords

All cause mortality; Cardio vascular disease mortality; Coronary artery disease mortality; Dyslipidemic; Meta analysis

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRATE; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DYSLIPIDEMIA; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SAMPLE SIZE; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

EID: 64149130648     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.48878     Document Type: Review

References (26)

1. Pandey R. Cardiovascular disease in India and the impact of lifestyle and food habits [online]. 2004 Dec [last accessed on 2006 Apr 21]. Available from: http:// www.expresshealthcaremgmt.com/20041215/criticare06.shtml.
2. Hebert PR, Gaziano M, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality an overview of randomized trials. JAMA 1997;278:313-21.
3. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
4. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomized trials. BMJ 2000;321: 983-6.
5. Sever PS, Dahlor B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003;361:1149-58.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of Coronary heart disease with pravastatin in men with hypercholestrolemia: The West of Scotland Coronary Prevention Study Group (WOSCOPS). N Engl J Med 1995;333:1301-7.
7. Rubins Hanna B, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of Coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
8. LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
9. Sacks FM, Pleffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: The Cholesterol and Recurrent Events Trial (CARE). N Engl J Med 1996;335:1001-9.
10. Downs John R, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
11. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary Angiographic Changes with Lovastatin Therapy (MARS). Ann Intern Med 1993;119:969-76.
12. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 2002;360:1623-30.
13. Study Group of Physicians of the Newcastle. Trial of Clofibrate in the treatment of Ischemic heart disease. BMJ 1971;4:767-75.
14. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, et al. Effect of fluvastatin on ischemia following acute myocardial infarction: A randomized trial. Eur Heart J 2002;23:1931-7.
15. PLAC-I Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I): Reduction in atherosclerosis progression and clinical events. J A Coll Cardiol 1995;26:1133-9.
16. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids, and Atherosclerosis in the carotid Arteries (PLAC-II). Am J Cardiol 1995;75:455-9.
17. Scandinavian Simvastatin Survival Study Group. Randomised Trial of Cholesterol Lowering In 4444 Patients With Coronary Heart Disease. Lancet 1994;344:1383.
18. MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
19. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995;92:2404-10.
20. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and Cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS). Circulation 1994;90:1679-87.
21. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-64.
22. Jukema JW, Bruschke AG, van Boven JV, Reiber JH, Bal ET, Zwinderman AH, et al. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
24. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of Cardiac Events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-22.
25. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of Therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-24.
26. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al. Clinical outcomes in statin treatment trials: A meta-analysis. Arch Intern Med 1999;159:1793-802.